15262 Cardio-metabolic effects of long-term treatment with secukinumab in psoriatic arthritis and ankylosing spondylitis patients: Pooled 3 year analysis

      Introduction: Systemic inflammation may increase the risk of cardiovascular disorders in psoriasis (PsO), comorbid psoriatic arthritis (PsA), and ankylosing spondylitis (AS) patients. Secukinumab, a fully human monoclonal antibody that directly inhibits interleukin-17A, has demonstrated sustained efficacy and safety in patients with PsO, AS and PsA. Here, we report the long-term effects of secukinumab on key cardiometabolic parameters from pooled analysis of phase 3 clinical trials, through 156 weeks in AS/PsA patients.
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect